Latest Regulatory Engagement News

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

Felix Gold Limited has made significant strides in transitioning its Treasure Creek project from exploration to operational readiness, positioning itself as a key domestic supplier of critical antimony for the U.S. market.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

Yugo Metals has raised $3.5 million to fund its first-ever diamond drilling program targeting gold anomalies at its Sinjakovo project in Bosnia. The company also advances community and regulatory engagement for its Sockovac license while maintaining a cautious cash position.

Echo IQ Limited has advanced its EchoSolv heart failure solution towards FDA submission, driven by a landmark clinical validation study and a sharp rise in US platform adoption. Strategic partnerships and international expansion efforts underscore the company’s growing footprint in cardiology AI.

Elementos Limited advances its Oropesa Tin Project in Spain and Cleveland Tin Project in Tasmania, securing a binding option to acquire 50% of a Spanish tin smelter, positioning itself as the European Union’s primary vertically integrated tin producer amid strong tin prices.

Lion Energy Limited reports strategic progress on its East Seram drilling plans and limits spending on its Port of Brisbane Green Hydrogen Project pending government funding, while divesting a stake in the Seram Non-Bula PSC to reduce exposure.

Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

LGI Limited has launched a $5 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy additional shares at a slight discount. The capital raise aims to fund the acceleration of key renewable energy projects.